New formulations of fentanyl for acute pain management

Drugs of Today

Volumn 48, Issue 2, 2012, Pages 119-132

  Paech, Michael J ^a,b   Bloor, M ^b   Schug, S A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Breakthrough pain; Cancer pain; Fentanyl; Opioid

Indexed keywords

BREAKYL; BUQUEL; CHELATING AGENT; CHITOSAN; CYCLODEXTRIN; DIAMORPHINE; FENTANYL; FENTANYL CITRATE; LIPOSOME; MACROGOL; METHANOL; METHOXYFLURANE; MORPHINE; NASALFENT; PECSYS; PECTIN; PLACEBO; POLOXAMER; PROPYLENE GLYCOL; SUBSYS; SURFACTANT; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE VESICLE; AREA UNDER THE CURVE; BREAKTHROUGH PAIN; CANCER PAIN; CHRONIC PAIN; CINAHL; COCHRANE LIBRARY; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG WITHDRAWAL; EFFERVESCENT TABLET; EMBASE; EPISTAXIS; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; HEADACHE; HUMAN; HYPOTENSION; IONTOPHORESIS; LOZENGE; MEDICAL NEBULIZER; MEDLINE; METERED DOSE INHALER; MINIPUMP; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NOSE IRRITATION; PAIN; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SYSTEMATIC REVIEW; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACUTE PAIN; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CHEMISTRY, PHARMACEUTICAL; FENTANYL; HUMANS;

EID: 84858231796     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.2.1745275     Document Type: Review

References (109)

1. Stanley, T.H. The history and development of the fentanyl series. J Pain Symptom Manage 1992, 7(3): S3-7.
2. Peng, P.W.H., Sandler, A.N. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999, 90(2): 576-99. (Pubitemid 29071528)
3. The British Pain Society. Opioids for Persistent Pain: Good Practice. 2010. Available from: http://www.britishpainsociety.org/book-opioid-main.pdf. Accessed November 28, 2011. Last updated January 2010.
4. O'Connor, A.B. Is Actiq use in noncancer-related pain really "a recipe for success"? Pain Med 2008, 9(2): 258-60. (Pubitemid 351285423)
5. Leppert, W. Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Manag Res 2010, 2: 225-32.
6. Lim, C.B., Schug, S., Sunderland, B.V., Liu, Y., Paech, M.J. A phase one pharmacokinetic study of a sublingual fentanyl wafer in healthy volunteers. Anesth Analg 2012, in press.
7. Bushnaq, M., Al-Shoubaki, M., Milhem, M. The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer. J Palliat Med 2009, 12(6): 511-4.
8. Dale, O., Hjortkjaer, R., Kharasch, E.D. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002, 46(7): 759-70. (Pubitemid 34803193)
9. Illum, L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci 2007, 96(3): 473-83. (Pubitemid 46466073)
10. Gizurarson, S. The relevance of nasal physiology to design of drug absorption studies. Adv Drug Deliv Rev 1993, 11: 329-47. (Pubitemid 23302851)
11. Stiebel, H.W., Wessel, A., Rieger, A. Intranasal fentanyl for breakthrough cancer pain. A pilot study. Schmerz 1993, 7(3): 174-7.
12. Zappetella, G., Ribeiro, M.D. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006, (1): CD004311.
13. Toussaint, S., Maidl, J., Schwagmeier, R. et al. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief. Can J Anaesth 2000, 47(4): 299-302.
14. O'Neil, G., Paech, M., Wood, F. Preliminary clinical use of a patient-controlled intranasal analgesia (PCINA) device. Anaesth Intensive Care 1997, 25(4): 408-12. (Pubitemid 27389204)
15. Paech, M.J., Lim, C.B., Banks, S.L. et al. A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study. Anaesthesia 2003, 58(8): 740-4. (Pubitemid 36934565)
16. Lim, S.C.B., Paech, M.J., Sunderland, V.B., Roberts, M.J., Banks, S.L., Rucklidge, M.W.M. Pharmacokinetics of nasal fentanyl. J Pharm Pract 2003, 33(1): 59-63. (Pubitemid 36433802)
17. Valdhorst-Janssen, N.M., Fiddelers, A.A., van der Kuy, P.H. et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin Ther 2010, 32(7): 1427-36.
18. Fisher, A., Watling, M., Smith, A., Knight, A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010, 48(2): 138-45.
19. Moksnes, K., Fredheim, O.M., Klepstad, P., Kaasa, S., Angelsen, A., Nilsen, T., Dale, O. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008, 64(5): 497-502.
20. Kaasa, S., Moksnes, K., Nolte, T., Lefebvre-Kuntz, D., Popper, L., Kress, H.G. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010, 6(1): 17-26.
21. Foster, D., Upton, R., Christrup, L., Popper, L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 2008, 42(10): 1380-7.
22. Pennington, A.K., Ratcliffe, J.H., Wilson, C.G., Hardy, J.G. The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm 1988, 43: 221-4.
23. Watts, P., Smith, A. PecSys: In situ gelling system for optimized nasal drug delivery. Expert Opin Drug Deliv 2009, 6(5): 543-52.
24. Portenoy, R.K., Burton, A.W., Gabrail, N., Taylor, D. A multicentre, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010, 151(3): 617-24.
25. Taylor, D., Galan, V., Weinstein, S.M. et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010, 8(4): 184-90; erratum in 8(5): 201.
26. Portenoy, R.K., Raffaeli, W., Torres, L.M., Sitte, T., Deka, A.C., Herrera, I.G., Wallace, M.S. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag 2010, 6(5): 319-28.
27. Kress, H.G., Oronska, A., Kaczmarek, Z., Kaasa, S., Colberg, T., Nolte, T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, doubleblind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009, 31(6): 1177-91.
28. Davies, A., Sitte, T., Elsner, F., Reale, C., Espinosa, J., Brooks, D., Fallon, M. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate in breakthrough cancer pain. J Pain Symptom Manage 2011, 41(2): 358-66.
29. Fallon, M., Gatti, A., Davies, A., Lux, E.A., Kumar, K., Galvez, R.; on behalf of the Fentanyl Nasal Spray Study 044 Investigators Group. Fentanyl pectin nasal spray provides clinically meaningful pain relief and a more rapid onset of analgesia compared with immediate-release morphine sulphate in breakthrough cancer pain. Palliative Med 2010, 24: Abst S24.
30. Mercandante, S., Radbruch, L., Davies, A. et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009, 25(11): 2805-15.
31. Vissers, D., Stam, W., Nolte, T., Lenre, M., Jansen, J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010, 26(5): 1037-45.
32. Stam, W., Vissers, D., Lenre, M. et al. An economic evaluation of fast-acting opioids for the treatment of breakthrough pain in cancer patients in Sweden. Eur J Pain 2009, 13(Suppl. 1): S241.
33. Davis, M.P. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother 2011, 11(8): 1197-216.
34. Leppert, W. Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Manag Res 2010, 2: 225-32.
35. Prommer, E., Thompson, L. Intranasal fentanyl for pain control: current status with a focus on patient considerations. Patient Prefer Adherence 2011, 5: 157-164.
36. Mudd, S. Intranasal fentanyl for pain management in children: a systematic review of the literature. J Pediatr Health Care 2011, 25(5): 316-22.
37. Shelley, K., Paech, M.J. The clinical applications of intranasal opioids. Curr Drug Deliv 2008, 5(1): 55-8. (Pubitemid 351225634)
38. Striebel, H.W., Oelmann, T., Spies, C., Rieger, A., Schwagmeier, R. Patient-controlled intranasal analgesia: a method for non-invasive postoperative pain management. Anesth Analg 1996, 83(3): 548-51. (Pubitemid 26296364)
39. Toussaint, S., Maidl, J., Schwagmeier, R., Striebel, H.W. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for post-operative pain relief. Can J Anaesth 2000, 47(4): 299-302.
40. Christup, L.L, Foster, D., Popper, L.D., Troen, T., Upton, R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, doubleblind, double-dummy, two-way, crossover study. Clin Ther 2008, 30(3): 469-81. (Pubitemid 351483922)
41. Galinkin, J.L., Fazi, L.M., Guy, R.M. et al. Use of IN fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology 2000, 93(6): 1378-83.
42. Manjushree, R., Lahiri, A., Ghosh, B.R. et al. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can J Anaesth 2002, 49(2): 190-3. (Pubitemid 34189346)
43. Wong, P., Chadwick, F.D., Karovits, J. Intranasal fentanyl for postoperative analgesia after elective Caesarean section. Anaesthesia 2003, 58(8): 818-9. (Pubitemid 36934601)
44. Borland, M., Jacobs, I., King, B. et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med 2007, 49(3): 335-40.
45. Johnston, S., Wilkes, G.J., Thompson, J.A., Ziman, M., Brightwell, R. Inhaled methoxyflurane and intranasal fentanyl for prehospital management of visceral pain in an Australian ambulance service. Emerg Med J 2011, 28(1): 57-63.
46. Bendall, J.C., Simpson, P.M., Middleton, P.M. Effectiveness of prehospital morphine, fentanyl, and methoxyflurane in pediatric patients. Prehosp Emerg Care 2011, 15(2): 158-65.
47. Rickard, C., O'Meara, P., McGrail, M., Garner, D., McLean, A., Le Lievre, P. A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting. Am J Emerg Med 2007, 25(8): 911-7. (Pubitemid 47516642)
48. Clinical Effectiveness Committee of the College of Emergency Medicine. Guideline for the management of pain in children. http://secure. collemergencymed.ac.uk/asp/document.asp?ID=4682. Accessed November 28, 2011. Last updated May 2010.
49. Watkins, N. Paediatric prehospital analgesia in Auckland. Emerg Med Australas 2006, 18(1): 51-6.
50. Cole, J., Shepherd, M., Young, P. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg Med Australas 2009, 21(5): 395-400.
51. Saunders, M., Adelgais, K., Nelson, D. Use of intranasal fentanyl for the relief of pediatric orthopaedic trauma pain. Acad Emerg Med 2010, 17(11): 1155-61.
52. Finn, J., Wright, J., Fong, J., Mackenzie, E., Wood, F., Leslie, G., Gelavis, A. A randomised crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adult patients with burns. Burns 2004, 30(3): 262-8. (Pubitemid 38479907)
53. Crellin, D., Ling R.X., Babi, F.E. Does the standard intravenous solution of fentanyl (50 microg/ml) administered intranasally have analgesic efficacy? Emerg Med Australas 2010, 22(1): 62-7.
54. Borland, M., Milsom, S., Esson, A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: A randomized controlled trial. Emerg Med Australas 2011, 23(2): 202-8.
55. Borland, M.L., Bergesio, R., Pascoe, E.M., Turner, S., Woodger, S. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns 2005, 31(7): 831-7. (Pubitemid 41394138)
56. Study finds 90 percent of Actiq "lollipop" prescriptions are off-label [news release]. Prime Therapeutics, January 16, 2007. http://www.prime therapeutics.com/pdf/Actiq.pdf. Accessed November 28, 2011.
57. Mystakidou, K., Katsouda, E., Parpa, E., Vlahos, L. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv 2006, 13(4): 269-76. (Pubitemid 43739138)
58. Grape, S., Schug, S.A., Lauer, S., Schug, B.S. Formulations of fentanyl for the management of pain. Drugs 2010, 70(1): 57-72.
59. Mandel, L., Carunchio, M.J. Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. J Am Dent Assoc 2011, 142(4): 406-9.
60. Chwieduk, C.M., McKeage, K. Fentanyl sublingual in breakthrough pain in opioid-tolerant adults with cancer. Drugs 2010, 70(17): 2281-8.
61. Bredenberg, S., Duberg, M., Lennernas, B. et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003, 20(3): 327-34. (Pubitemid 37338538)
62. Lennernas, B., Hedner, T., Holmberg, M., Bredenberg, S., Nystrom, C., Lennernas, H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2004, 59(2): 249-53. (Pubitemid 40208864)
63. Darwish, M., Xie, F. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. Pain Pract 2011, Epub ahead of print.
64. Darwish, M., Kirby, M., Jiang, J.G., Tracewell, W., Robertson, P. Jr. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin Drug Investig 2008, 28(1): 1-7. (Pubitemid 350274395)
65. Vasisht, N., Gever, L.N., Tagarro, I., Finn, A. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate. Clin Drug Investig 2009, 29(10): 647-54.
66. Vasisht, N., Gever, L.N., Tagarro, I., Finn, A.L. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010, 11: 1017-23.
67. Coluzzi, P.H., Schwartzberg, L., Conroy, J.D. et al. Breakthrough cancer pain: a randomised trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001, 91(1-2): 575-83.
68. Burton, A.W., Driver, L.C., Mendoza, T.R. et al. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series. Clin J Pain 2004, 20(3): 195-7. (Pubitemid 38544040)
69. Blick, S., Wagstaff, A.J. Fentanyl buccal tablets in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006, 66(18): 2387-93. (Pubitemid 46072453)
70. Ashburn, M.A., Slevin, K.A., Messina, J., Xie, F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011, 112(3): 693-702.
71. Lister, N., Warrington, S., Boyce, M., Eriksson, C., Tamaoka, M., Kilborn, J. Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. J Clin Pharmacol 2011, 51(8): 1195-204.
72. Portenoy, R.K., Taylor, D., Messina, J. et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006, 22(9): 805-11. (Pubitemid 44627444)
73. Slatkin, N.E., Xie, F., Messina, J. et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007, 5(7): 327-34. (Pubitemid 350055013)
74. Portenoy, R.K., Messina, J., Xie, F. et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007, 23(1): 223-33. (Pubitemid 46191684)
75. Simpson, D.m., Messina, J., Xie, F. et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicentre, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29(4): 588-601. (Pubitemid 47016640)
76. Weinstein, S.M., Messina, J., Xie, F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009, 115(11): 2571-9.
77. Rauck, R.L., Tark, M., Reyes, E. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009, 25(12): 2877-85.
78. Uberall, M.A., Muller-Schwefe, G.H. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 2011, 27(7): 1385-94.
79. Fine, P.G. Pain-final common pathways: pathophysiology and pragmatism. Reg Anesth Pain Med 2000, 25(1): 1-2. (Pubitemid 30059168)
80. Lichtor, J.L., Sevarino, F.B., Joshi, G.P. et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 1999, 89(3): 732-8. (Pubitemid 29409831)
81. Sharar, S.R., Bratton, S.L., Carrougher, G.J. et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J Burn Care Rehabil 1998, 19(6): 516-21. (Pubitemid 28549805)
82. Schechter, N.L., Weisman, S.J., Rosenblum, M., Bernstein, B., Conard, P.L. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics 1995, 95(3): 335-9.
83. Landy, S.H. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series. Headache 2004, 44(8): 762-6. (Pubitemid 39310959)
84. Shaiova, L., Wallenstein, D. Outpatient management of sickle cell pain with chronic opioid pharmacotherapy. J Natl Med Assoc 2004, 96(7): 984-6. (Pubitemid 38823515)
85. Sharar, S.R., Carrougher, G.J., Selzer, K. et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil 2002, 23(1): 27-31. (Pubitemid 34072722)
86. Adverse Events, Inc. Actiq. http://www.adverseevents.com/drugdetail.php? AEDrugID=235&BrandName=Actiq&more=drugname. Accessed November 28, 2011. Last updated June 2011.
87. US Food and Drug Administration. Important Safety Information for Fentora. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/UCM154439.pdf. Accessed November 16, 2011. Last updated September 2007.
88. US Food and Drug Administration. Questions and answers about Onsolis (fentanyl buccal soluble film). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm172039.htm. Accessed November 28, 2011. Last updated July 2009.
89. .Worsley, M.H., MacLeod, A.D., Brodie, M.J., Asbury, A.J., Clark, C. Inhaled fentanyl as a method of analgesia. Anaesthesia 1990, 45(6): 449-51. (Pubitemid 20215821)
90. Higgins, M.J., Asbury, A.J., Brodie, M.J. Inhaled nebulised fentanyl for postoperative analgesia. Anaesthesia 1991, 46(11): 973-6.
91. Hung, O.R., Whynot, S.C., Varvel, J.R., Shafer, S.L., Mezei, M. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology 1995, 83(2): 277-84.
92. Mather, L.E., Woodhouse, A., Ward, M.E., Farr, S.J., Rubsamen, R.A., Eltherington, L.G. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol 1998, 46(1): 37-43. (Pubitemid 28308422)
93. Bartfield, J.M., Flint, R.D., McErlean, M., Broderick, J. Nebulized fentanyl for relief of abdominal pain. Acad Emerg Med 2003, 10(3): 215-8. (Pubitemid 36292622)
94. Manning, H.L. Dyspnea treatment. Respir Care 2000, 45(11): 1342-51. (Pubitemid 33127045)
95. Coyne, P.J., Viswanathan, R., Smith, T.J. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002, 23(2): 157-60. (Pubitemid 34158649)
96. Graff, G.R., Stark, J.M., Grueber, R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration 2004, 71(6): 646-9. (Pubitemid 40091441)
97. Mayes, S., Ferrone, M. Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann Pharmacother 2006, 40(12): 2178-86.
98. Camu, F., Van Aken, H., Bovill, J.G. Postoperative analgesic effects of three demand-dose sizes of fentanyl administered by patients-controlled analgesia. Anesth Analg 1998, 87(4): 890-5. (Pubitemid 28455489)
99. Gupta, S., Hwang, S., Southam, M., Sathyan, G. Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). Clin Pharmacokinet 2005, 44(Suppl. 1): 25-32. (Pubitemid 41626714)
100. .Sathyan, G., Zomorodi, K., Gidwani, S., Gupta, S. The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS). Clin Pharmacokinet 2005, 44(Suppl. 1): 17-24. (Pubitemid 41626713)
101. Chelly, J.E., Grass, J., Houseman, T.W., Minkowitz, H., Pue, A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicentre, placebo-controlled trial. Anesth Analg 2004, 98(2): 427-33. (Pubitemid 38129392)
102. .Viscusi, E.R., Reynolds, L., Tait, S., Melson, T., Atkinson, L.E. An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: A double blind, placebo-controlled trial. Anesth Analg 2006, 102(1): 188-94. (Pubitemid 43038306)
103. .Grond, S., Hall, J., Spacek, A., Hoppenbrouwers, M., Richarz, U., Bonnet, F. Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management. Br J Anaesth 2007, 98(6): 806-15. (Pubitemid 47072593)
104. .Hartrick, C.T., Bourne, M.H., Gargiulo, K., Damaraju, C.V., Vallow, S., Hewitt, D.J. Fentanyl iontophoretic transdermal system for acute pain management after orthopaedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med 2006, 31(6): 546-54. (Pubitemid 44810090)
105. .Minkowitz, H.S., Rathmell, J.P., Vallow, S., Gargiulo, K., Damaraju, C.V., Hewitt, D.J. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med 2007, 8(8): 657-68. (Pubitemid 350142913)
106. .Viscuri, E.R., Reynolds, L., Chung, F. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: A randomized controlled trial. JAMA 2004, 291(11): 1333-41. (Pubitemid 38541648)
107. Poon, K.H., Tan, K.H., Ho, K.Y. Efficacy of fentanyl iontophoretic transdermal system in postoperative pain - a meta-analysis. Acute Pain 2009, 11: 65-74.
108. .Pennington, P., Caminiti, S., Schein, J.R., Hewitt, D.J., Nelson, W.W. Patients' assessment of the convenience of fentanyl HCl iontophoretic transdermal system (ITS) versus mor- phine intravenous patient-controlled analgesia (IV PCA) in the management of postoperative pain after major surgery. Pain Manag Nurs 2009, 10(3): 124-33.
109. .European Medicines Agency. Ionysys (fentanyl): non-renewal of the marketing authorisation in the European Union. http://www.ema.europa.eu/docs/en- GB/document-library/Public-statement/2011/01/WC500101495.pdf. Accessed November 28, 2011. Last updated January 2011.